Prevention of Postpartum Hemorrhage in Patients With Severe Preeclampsia Using Carbetocin Versus Misoprostol

• Status: Completed
• Trial end date: 2015-08-01
• Target enrollment: 0
• Participant gender: Female

Summary

We aim to compare carbetocin with misoprostol for the prevention of postpartum hemorrhage in patients with severe preeclampsia. The primary outcome is postpartum haemorrhage (blood loss of ≥ 500 ml) while our Secondary outcomes include use of additional uterotonics, need for blood transfusion, maternal adverse drug reaction, maternal complications and maternal death

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: khalid abd aziz mohamed
• Treatments: Carbetocin; Misoprostol; Oxytocin

Criteria

Inclusion Criteria:

• Women with singleton pregnancies of more than 28 weeks' gestation who were admitted to hospital with severe preeclampsia and candidates for vaginal delivery were eligible for the study. Preeclampsia is labelled as severe in the presence of any of the following abnormalities:

1. Persistent cerebral or visual disturbances or cerebral edema.

2. Persistent epigastric pain with nausea or vomiting, or both.

3. Systolic ≥160 mmHg or diastolic ≥110 mmHg on 2 occasions at least 6 h apart with the patient at bed rest.

4. Proteinuria of ≥5 g on 24-hour urine collection. Urine dipsticks are not accurate for this purpose.

5. Oliguria (˂500 mL in 24 hours).

6. Pulmonary edema.

7. Thrombocytopenia.

Exclusion Criteria:

• were HELLP syndrome, eclampsia, abruptio placentae, malpresentation, polyhydramnios, previous uterine scar, chorioamnionitis and multiple pregnancies